Company Profile

Tiba Biotech LLC
Profile last edited on: 4/4/22      CAGE: 7QLV7      UEI: XNL9ZSLHN795

Business Identifier: {re-clinical biotech: next generation RNA vaccines and therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

One Broadway Floor 14
Cambridge, MA 02142
   (617) 401-3055
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

Structured around integrated nanoparticle delivery and nucleic acid design, Tiba Biotech LLC is addressing development of life-saving vaccines and new areas of therapeutic impact: creation of a new generation of vaccines and immunotherapies for human and animal disease. Bridging expertise in synthetic biology and chemistry to bring more potent and cost-effective solutions to the market. the vision is of a world where affordable vaccines and therapeutics can be developed in response to epidemics and specific patient needs, without the need for protracted biomanufacturing processes. Engaged in early discovery of immuno-oncology and gene editing, the effort is to tackle a range of novel vaccines, with initial focus on the COVID-19 pandemic and the persistent challenge of seasonal influenza.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $278,957
Project Title: RNA-based multi-antigen vaccine for SARS-CoV-2

Key People / Management

  Karl Ruping -- Founder and CEO

  Christian W Mandl -- CCo-Founder. ACting Chief Scientific Officer

  Peter Mcgrath -- Chief Financial Officer

  Justine McPartlan -- Associate Scientist

  Poulami Talukder -- Senior Scientist

Company News

There are no news available.